How much funding has Spectral Platforms raised?

Spectral Platforms has disclosed $675K raised across 1 round.

Where is Spectral Platforms headquartered?

Spectral Platforms is headquartered in Monrovia, US.

Spectral Platforms

Monrovia, US · Delaware corporation

Spectral Platforms develops diagnostic technology to detect bacterial infections and antimicrobial susceptibility faster than traditional microbiology methods. It aims to test clinical samples directly for markers associated with bacterial presence, targeting blood and urine testing that conventionally requires 24-48 hours of culturing.

Biotech Deep Tech Healthtech

Founders & leadership

CJ YUExecutive

RAVI VERMANamed on SEC filing

Board

SCOTT FRASERBoard director

RUSS CRAIGBoard director

Reported raises · per SEC filings

Form D private placements

$675K disclosed across 1 round · 2015

▶$675KraisedJul 2015 · 14 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

RAVI VERMAExecutive Officer, Director
SCOTT FRASERDirector
RUSS CRAIGDirector
CJ YUExecutive Officer, Director

Offering amount: $1.4M
Amount sold: $675K
Minimum investment: $5K
Proceeds to insiders: $100K
First sale: Jul 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

BioMérieux4 shared keywordsbioMérieux develops in vitro diagnostic solutions for clinical laboratories and healthcare professionals, covering areas such as antimicrobial stewardship, sepsis, and infectious disease detection. It also provides diagnostics for food safety and quality and pharmaceutical quality control.

iFAST3 shared keywordsiFAST Diagnostics develops a rapid antimicrobial susceptibility testing (AST) system that uses a microfluidic impedance chip to measure the electrical properties of individual bacteria, delivering resistant/susceptible and MIC results from Gram-negative blood cultures or bacterial isolates in under three hours. The technology is aimed at hospital clinical microbiology labs and clinicians to guide antibiotic prescribing and combat antimicrobial resistance, with a focus on the UK market.

Companies competing with Spectral Platforms for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
U.S. ArmyArmy	Phase II	2013	$1.9M
Department of DefenseDefense Health Program	Phase I	2012	$150K
U.S. ArmyArmy	Phase I	2011	$148.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Spectral Platforms do?: Spectral Platforms develops diagnostic technology to detect bacterial infections and antimicrobial susceptibility faster than traditional microbiology methods. It aims to test clinical samples directly for markers associated with bacterial presence, targeting blood and urine testing that conventionally requires 24-48 hours of culturing.
How much funding has Spectral Platforms raised?: Spectral Platforms has disclosed $675K raised across 1 round.
Where is Spectral Platforms headquartered?: Spectral Platforms is headquartered in Monrovia, US.